Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Moodys
Baxter
Colorcon

Last Updated: August 19, 2022

COMETRIQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Cometriq, and when can generic versions of Cometriq launch?

Cometriq is a drug marketed by Exelixis and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and seventy-six patent family members in thirty-one countries.

The generic ingredient in COMETRIQ is cabozantinib s-malate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

DrugPatentWatch® Generic Entry Outlook for Cometriq

Cometriq was eligible for patent challenges on November 29, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2032. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for COMETRIQ
Drug Prices for COMETRIQ

See drug prices for COMETRIQ

DrugPatentWatch® Estimated Generic Entry Opportunity Date for COMETRIQ
Generic Entry Date for COMETRIQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for COMETRIQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OHSU Knight Cancer InstitutePhase 2
Oregon Health and Science UniversityPhase 2
Baptist Health South FloridaPhase 2

See all COMETRIQ clinical trials

Pharmacology for COMETRIQ
Drug ClassKinase Inhibitor
Mechanism of Action Protein Kinase Inhibitors

US Patents and Regulatory Information for COMETRIQ

COMETRIQ is protected by seven US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of COMETRIQ is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting COMETRIQ

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms therof for the treatment of cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N'-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms thereof for the treatment of cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING MEDULLARY THYROID CANCER

Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

c-Met modulators and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING MEDULLARY THYROID CANCER

Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for COMETRIQ

When does loss-of-exclusivity occur for COMETRIQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5155
Estimated Expiration: See Plans and Pricing

Australia

Patent: 12214322
Estimated Expiration: See Plans and Pricing

Patent: 17204877
Estimated Expiration: See Plans and Pricing

Patent: 19203745
Estimated Expiration: See Plans and Pricing

Patent: 20273307
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2013020362
Estimated Expiration: See Plans and Pricing

Canada

Patent: 26751
Estimated Expiration: See Plans and Pricing

China

Patent: 3459373
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 73262
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 3513
Estimated Expiration: See Plans and Pricing

Patent: 1391145
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 73262
Estimated Expiration: See Plans and Pricing

Georgia, Republic of

Patent: 0217235
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 57574
Estimated Expiration: See Plans and Pricing

Israel

Patent: 7848
Estimated Expiration: See Plans and Pricing

Japan

Patent: 13598
Estimated Expiration: See Plans and Pricing

Patent: 14505109
Estimated Expiration: See Plans and Pricing

Patent: 16188216
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 13009116
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 4130
Estimated Expiration: See Plans and Pricing

Patent: 2808
Estimated Expiration: See Plans and Pricing

Poland

Patent: 73262
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 73262
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1306072
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2030447
Estimated Expiration: See Plans and Pricing

Patent: 140044782
Estimated Expiration: See Plans and Pricing

Patent: 190049907
Estimated Expiration: See Plans and Pricing

Patent: 200031711
Estimated Expiration: See Plans and Pricing

Patent: 210010671
Estimated Expiration: See Plans and Pricing

Patent: 210147117
Estimated Expiration: See Plans and Pricing

Spain

Patent: 05571
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 40509
Estimated Expiration: See Plans and Pricing

Patent: 1309650
Estimated Expiration: See Plans and Pricing

Patent: 1706249
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COMETRIQ around the world.

Country Patent Number Title Estimated Expiration
Portugal 2210607 See Plans and Pricing
Spain 2369652 See Plans and Pricing
Croatia P20110707 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for COMETRIQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213661 300678 Netherlands See Plans and Pricing PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
2213661 43/2014 Austria See Plans and Pricing PRODUCT NAME: CABOZANTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/890/001-003 (MITTEILUNG) 20140326
2213661 220 50007-2014 Slovakia See Plans and Pricing PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
McKesson
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.